UNICA IRIS Institutional Research Information System

CAOCCI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 499.008
NA - Nord America 20.446
AS - Asia 9.721
SA - Sud America 1.655
Continente sconosciuto - Info sul continente non disponibili 1.092
AF - Africa 247
OC - Oceania 64
Totale 532.233
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 488.691
US - Stati Uniti d'America 20.041
NL - Olanda 5.129
SG - Singapore 3.751
CN - Cina 3.064
BR - Brasile 1.272
SE - Svezia 1.263
UA - Ucraina 1.159
VN - Vietnam 995
FI - Finlandia 699
GB - Regno Unito 526
DE - Germania 511
FR - Francia 505
HK - Hong Kong 382
IN - India 334
CA - Canada 225
KR - Corea 218
BD - Bangladesh 173
AR - Argentina 139
IQ - Iraq 111
MX - Messico 93
AT - Austria 92
JP - Giappone 90
TR - Turchia 78
ZA - Sudafrica 76
PL - Polonia 74
RU - Federazione Russa 73
EC - Ecuador 68
PK - Pakistan 64
AU - Australia 55
IR - Iran 54
ID - Indonesia 49
SA - Arabia Saudita 46
VE - Venezuela 46
IE - Irlanda 44
MY - Malesia 42
ES - Italia 41
MA - Marocco 37
BE - Belgio 33
CO - Colombia 32
PH - Filippine 32
CL - Cile 27
UZ - Uzbekistan 27
AE - Emirati Arabi Uniti 26
EG - Egitto 24
JO - Giordania 23
TH - Thailandia 23
CZ - Repubblica Ceca 22
PY - Paraguay 21
JM - Giamaica 20
CH - Svizzera 19
KE - Kenya 19
LT - Lituania 19
TN - Tunisia 19
PE - Perù 18
IL - Israele 17
RO - Romania 17
UY - Uruguay 17
ET - Etiopia 16
DZ - Algeria 15
AZ - Azerbaigian 14
CR - Costa Rica 14
BO - Bolivia 13
KZ - Kazakistan 13
OM - Oman 13
NP - Nepal 12
BG - Bulgaria 11
DK - Danimarca 11
EU - Europa 11
TW - Taiwan 11
LB - Libano 10
GE - Georgia 9
PA - Panama 9
PS - Palestinian Territory 9
PT - Portogallo 9
BY - Bielorussia 8
NZ - Nuova Zelanda 8
TT - Trinidad e Tobago 8
GR - Grecia 7
HU - Ungheria 7
NG - Nigeria 7
PR - Porto Rico 7
DO - Repubblica Dominicana 6
NI - Nicaragua 6
SY - Repubblica araba siriana 6
KG - Kirghizistan 5
MD - Moldavia 5
SK - Slovacchia (Repubblica Slovacca) 5
AL - Albania 4
AM - Armenia 4
CI - Costa d'Avorio 4
HN - Honduras 4
HR - Croazia 4
LV - Lettonia 4
MU - Mauritius 4
NO - Norvegia 4
QA - Qatar 4
RS - Serbia 4
BW - Botswana 3
CG - Congo 3
Totale 531.096
Salva come PNG Salva come JPEG
Città #
Cagliari 460.504
Uta 26.252
Amsterdam 5.042
Ashburn 1.855
Singapore 1.808
Fairfield 1.726
Woodbridge 1.328
San Jose 1.171
Dallas 1.088
Boardman 981
Houston 899
Chandler 846
Wilmington 712
Nyköping 709
Seattle 707
Ann Arbor 690
Cambridge 618
Jacksonville 598
Beijing 596
Council Bluffs 540
Los Angeles 480
Helsinki 474
New York 467
Hong Kong 340
Ho Chi Minh City 298
Lauterbourg 273
Hefei 269
Santa Clara 257
Nanjing 217
Boston 216
Seoul 199
Milan 180
Hanoi 177
Dong Ket 170
Rome 170
Shanghai 166
The Dalles 157
Buffalo 153
Dearborn 126
San Diego 122
São Paulo 117
Chicago 104
Guangzhou 94
Orem 90
Atlanta 84
Columbus 84
Redondo Beach 84
Toronto 76
Munich 71
London 70
Redwood City 67
Shenyang 67
Phoenix 66
Tokyo 64
Nanchang 61
Tianjin 61
Brooklyn 59
Frankfurt am Main 59
Hebei 59
Chennai 58
Menlo Park 58
Rio de Janeiro 58
Nuremberg 57
Changsha 56
Mountain View 56
Denver 55
Warsaw 54
Norwalk 45
San Francisco 44
Vienna 43
Baghdad 42
Washington 42
Da Nang 41
Johannesburg 41
Haiphong 39
Jiaxing 39
Manchester 37
Montreal 36
Pune 35
Verona 35
Orange 33
Jinan 32
Sassari 32
Mumbai 30
Brussels 29
Falls Church 29
Lappeenranta 28
Wuhan 28
Zhengzhou 27
Hangzhou 26
Naples 26
Paris 26
Tashkent 26
Detroit 25
Shenzhen 25
New Delhi 24
Stockholm 24
Düsseldorf 23
Bologna 22
Poplar 22
Totale 516.526
Salva come PNG Salva come JPEG
Nome #
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome 242.328
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.580
Leucocyte classification for leukaemia detection using image processing techniques 3.608
HLA-G expression and role in advanced-stage classical Hodgkin lymphoma 3.587
Comparison Between an Artificial Neural Network and Logistic Regression in Predicting Long Term Kidney Transplantation Outcome 3.439
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 3.416
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.372
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.349
What unrelated hematopoietic stem cell transplantation in thalassemia taught us about transplant immunogenetics 3.322
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 3.319
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 3.239
Reassessing the approach to informed consent: The case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 3.062
Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study 2.925
KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation 2.921
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.834
Ruolo del trapianto allogenico nelle talassemie 2.795
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma 2.751
Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib 2.722
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.612
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients 2.609
A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes 2.525
Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia 2.258
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.256
Health related quality of life in patients with onco-hematological diseases 2.246
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 2.199
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 2.129
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 2.122
Role of human leukocyte antigen-G 14-base pair polymorphism in kidney transplantation outcomes 2.118
Homozygosity for Killer Immunoglobin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma 2.062
Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 2.000
Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia 1.964
Ruxolitinib therapy and telomere length in myelofibrosis 1.961
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.949
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.880
Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis 1.841
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.841
THE HLA-G 14-BP POLYMORPHISM IS AN INDEPENDENT GENETIC RISK MARKER OF LONG-TERM KIDNEY TRANSPLANTATION OUTCOME 1.818
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 1.807
The human leukocyte antigen-g 14-bp polymorphism is an independent genetic risk marker of long-term kidney transplantation outcome 1.763
null 1.759
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.759
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.692
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.621
Thresholds for clinical importance were defined for the EORTC CAT Core - an adaptive measure of core quality of life domains in oncology clinical practice and research 1.599
Acute basophilic leukemia with U2AF1 mutation 1.596
Defibrotide in the COVID-19 coagulopathy: what is the timing? 1.587
Systemic Mastocytosis with Associated Primary Myelofibrosis 1.581
Unrelated bone marrow transplantation in Thalassemia. The experience of the Italian Bone Marrow transplant Group (GITMO) 1.555
T cell tyrosine phosphorylation response to transient redox stress 1.555
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.542
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 1.541
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis 1.536
Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research 1.514
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.508
Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders? 1.488
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report 1.475
Successful and safe stem cell mobilization using plerixafor in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia 1.469
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency 1.462
Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation 1.455
Perls stain grade in bone marrow aspirate correlates with overall survival in low-risk myelodysplastic patients 1.452
Return to normal life after hematopoietic stem cell transplantation for thalassemia: a study of patients transplanted from matched sibling donors 1.444
null 1.419
Resolution of capillary leak syndrome by extracorporeal membrane oxygenation 1.415
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 1.405
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation 1.368
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 1.351
Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm 1.343
Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia 1.343
Immunological deregulation in classic hodgkin lymphoma 1.331
A simulated case of chronic myeloid leukemia: the growing risk of Munchausen’s Syndrome by internet 1.327
Rectal involvement in pre-early T acute lymphoblastic leukemia 1.310
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated donor hematopoietic stem cell transplantation in thalassemia patients 1.306
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 1.299
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major 1.282
Cytomegalovirus reactivation in patients under immunosuppressive treatment for autoimmune haemolytic anaemia 1.233
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination 1.233
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: A multicentre, prospective, observational, cohort study 1.222
The role of inhibitory KIR 2DL5 in the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma 1.219
White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy 1.205
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes 1.196
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation: a crystal ball to foresee the future? 1.178
Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment 1.155
null 1.138
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated haematopoietic stem cell transplantation 1.137
null 1.128
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index 1.116
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity 1.113
null 1.110
Complement-mediated oxidative damage of red cells impairs response to eculizumab in a G6PD-deficient patient with PNH 1.078
Paroxysmal nocturnal hemoglobinuria: clinical expression and response to treatment are modified by a unique interaction with co-existing glucose 6-phosphate dehydrogenase deficiency 1.065
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? 1.056
null 1.048
Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab 1.047
Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? 1.043
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis 1.043
null 1.034
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors 1.025
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 1.023
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). 1.015
Occurrence of immune thrombocytopenic purpura in a patient with essential thrombocythemia: How the immune system can overcome a neoplastic clone 1.011
Totale 422.089
Salva come PNG Salva come JPEG
Categoria #
all - tutte 656.299
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 656.299
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202215.648 0 1.367 820 915 1.235 1.281 835 875 1.405 2.021 2.587 2.307
2022/202322.185 1.654 2.475 2.451 1.687 2.012 2.372 961 2.724 1.364 1.400 2.052 1.033
2023/202426.605 1.275 1.050 1.468 1.954 2.229 4.706 3.680 1.828 1.345 2.031 2.505 2.534
2024/2025293.370 9.854 102.071 155.748 7.048 3.270 4.843 3.908 332 895 3.804 684 913
2025/202621.930 1.171 924 2.326 1.763 1.268 1.233 4.821 908 3.348 1.901 1.106 1.161
2026/20271.388 542 846 0 0 0 0 0 0 0 0 0 0
Totale 532.233